Combining FLT3 inhibitors with VTX could be a useful strategy to overcome Bcl-2 inhibitor resistance in FLT3-mutated AML patients and to prevent the appearance of FLT3-mutated subclones in patients with R/R AML [96,98,99,100,101,102,103,104]. Here, FLT3 is linked to acute myeloid leukemia.